Life Scientist > Biotechnology

R&D Tax Bill introduced to parliament

27 June, 2013

A Bill was yesterday introduced into parliament to jointly legislate for quarterly credits for companies entitled to the refundable 45% R&D Tax Incentive and to enact the $20 billion turnover cap for companies to be eligible for the 40% non-refundable R&D tax offset, as announced as part of the government’s A Plan for Australian Jobs in February.


Global Medisafe makes it to market

27 June, 2013 by Dylan Bushell-Embling

Global Medisafe Holdings has launched its first Clik-Lok safety syringe product in Europe and will soon start the process of securing Australian approval.


Biotech’s industry conference returns to Qld: early bird about to close

25 June, 2013

With early-bird registrations about to close (28 June), preparations have kicked into top gear at AusBiotech as the team prepares to return the industry event of the year to Brisbane, Queensland, from 30 October-1 November 2013.


GI Dynamics gets funding for French obesity trial

21 June, 2013 by Dylan Bushell-Embling

The French Government has agreed to fund a two-year economic impact study of GI Dynamics’ (ASX:GID) EndoBarrier Therapy in obesity and type 2 diabetes.


QBiotics launches $10m capital raising

20 June, 2013 by Dylan Bushell-Embling

QBiotics is involved in a $10m capital raising, seeking to raise funds for human studies of its anti-tumour candidate and research into the wound-healing potential of a new compound.


Grants available to partner with Massachusetts life sciences companies

20 June, 2013

A new funding program has recently been announced by the State of Victoria and the Commonwealth of Massachusetts to support joint research and development (R&D) projects.


WA researchers target key plant pathogen

19 June, 2013 by Dylan Bushell-Embling

Murdoch University scientists have developed a method for using gene silencing to control root lesion nematodes - plant pathogens which cause major agricultural damage.


iSonea picks manufacturing partner for AirSonea

19 June, 2013 by Dylan Bushell-Embling

iSonea (ASX:ISN) has engaged a Hong Kong manufacturer to produce its AirSonea mobile wheeze monitoring device, ahead of the product’s Australian launch in September.


AusBiotech delegation of CEOs to Parliament House

18 June, 2013

AusBiotech, its member CEOs and directors were yesterday hosted at Parliament House for this year’s CEO Forum, which was addressed by a range of speakers on innovation policy and programs, including the Hon Greg Combet, Minister for Climate Change, Industry and Innovation.


Pharmaxis presents new cystic fibrosis trial data

18 June, 2013 by Dylan Bushell-Embling

Pharmaxis (ASX:PXS) said CF patients receiving Bronchitol in recent phase III trials experienced fewer exacerbations long term than the control groups.


pSivida’s Iluvien close to UK reimbursement

17 June, 2013 by Dylan Bushell-Embling

The UK’s NICE has issued a draft decision recommending reimbursement of Iluvien, an ocular insert developed by pSivida (ASX:PVA), for pseudophakic DME patients.


QRxPharma wins US patent for opioid compounds

13 June, 2013

QRxPharma (ASX:QRX) has been granted a US patent covering linking morphine and oxycodone molecules to form a more potent hybrid compound.


Updates on agricultural biotechnology made easy

13 June, 2013

The Agricultural Biotechnology Council of Australia (ABCA) invites you to join its email list to receive regular updates on current and emerging issues in agricultural biotechnology in Australia.


UBI wins Vic government manufacturing award

12 June, 2013 by Dylan Bushell-Embling

Universal Biosensors (ASX:UBI) has picked up a Victorian government manufacturing award recognising innovative use of technology in its production processes.


Australian doctors back asthma system, says iSonea

12 June, 2013 by Dylan Bushell-Embling

iSonea (ASX:ISN) has released the results of a survey suggesting that 80% of Australian GPs and 62% of paediatricians would recommend its upcoming mobile wheeze-monitoring system.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd